Skip to main content
Clinical Trials/ChiCTR1800014854
ChiCTR1800014854RecruitingUnknown

变应性鼻炎患者特异性免疫治疗的分子生物学机制

本单位1 site in 1 country200 target enrollmentStarted: January 1, 2018Last updated:
Conditions

Trial Snapshot

Phase
Unknown
Status
Recruiting
Sponsor
Enrollment
200
Locations
1
Primary Endpoint
吸入性变应性血清 sIgE 检测

Study Overview

Brief Summary

通过对比免疫治疗前后在患者外周血和局部分泌液的基因的表达水平和细胞的免疫反应,阐明免疫治疗在变应性鼻炎治疗中的分子机理。

Study Design

Study Type
Observational

Eligibility Criteria

Ages
5 to 50 (—)
Sex
All

Inclusion Criteria

  • 患者根据症状、病史和鼻镜检查,诊断为过敏性鼻炎;
  • 无下呼吸道病变(如哮喘、慢性阻塞性肺炎、支气管扩张等)、无感染、无肿瘤和其他系统性疾病(如心脑血管病、糖尿病、慢性肝肾疾病等)

Exclusion Criteria

  • Not provided

Arms & Interventions

Case series

免疫治疗

Outcomes

Primary Outcomes

吸入性变应性血清 sIgE 检测

Time Frame: 服药前、服药后

视觉评分量表

Time Frame: 服药前、服药后

皮肤点刺

Time Frame: 服药前

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
本单位

Study Sites (1)

Loading locations...

Similar Trials